Management is focused on the Cancer Care Continuum strategy, aiming to capture more revenue per patient by offering a suite of tests from risk assessment to therapy selection and prognosis, designed to increase test utilization and reduce reliance on any single product. Hereditary cancer testing showed particularly strong momentum with 10% volume growth for full year 2025 and 12% in Q4, while mental health testing volumes grew 6% for the year despite headwinds from payer policy changes.
Cyborg Score Rationale
Myriad beat analyst expectations with adjusted EPS of $0.04 versus a forecasted loss of $0.02, with analysts predicting the company will return to profitability in 2026. The company maintained a strong liquidity position with $225 million in available capital as of December 31, 2025. However, revenue growth remains modest and competitive pressures persist in the genomic testing market.
Top Insights
Full year 2025 revenue of $824.5 million with adjusted gross profit of approximately $579 million and adjusted EBITDA of $39 million, maintaining strong liquidity of $225 million
Updated MyRisk HCT was launched in Q4 with plans to introduce disease-specific panels in 2026 to broaden addressable market
Successful execution of MRD launch and breadth of 2026 product catalysts will likely determine whether Myriad can restore investor confidence and close the valuation gap
2024 revenue was $837.60 million (11.21% increase YoY) with losses of -$127.30 million (51.65% improvement from 2023)
Named Competitors
Guardant Health — Liquid biopsy and oncology genomic testing
Veracyte — Molecular diagnostics for cancer and thyroid conditions
Natera — Reproductive and cancer genomic testing
NeoGenomics — Cancer diagnostics and companion diagnostics
Recent Developments
(March 2026) Stock trading at $5.01 with recent Q4 2025 earnings beat; analysts project return to profitability in 2026
(January 2026) Sam Raha announced as President and CEO; company provided 2026 financial guidance with strong growth expectations
(December 2025) Q4 2025 results showed adjusted EPS of $0.04 vs. forecasted loss of -$0.02; revenue of $209.8 million exceeded consensus; MRD launch positioned for 2026
Open the full interactive Myriad Genetics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.